$233,588,020
to LEIDOS BIOMEDICAL RESEARCH INC
NIAID COVID-19 ACTIV3
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Continuation of NIAID's COVID-19 ACTIV3 research program, an ongoing contract with Leidos Biomedical Research that began in 2020.
ACTIV3 accelerates development of therapeutics and vaccines for COVID-19 variants; this 2026 obligation sustains critical pandemic preparedness infrastructure through 2029.
Sustained funding for Leidos' biomedical research operations supports domestic vaccine and therapeutic manufacturing partnerships and clinical trial networks.
U.S. investment in domestic COVID-19 therapeutic and vaccine development reduces reliance on foreign supply chains for pandemic countermeasures.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-20. Cost: $0.003078.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75N91020F00039_7529_75N91019D00024_7529.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.